霍奇金淋巴瘤诊疗进展

Diagnosis and treatment progress of Hodgkin lymphoma

霍奇金淋巴瘤(HL)是起源于淋巴造血组织的恶性肿瘤,常侵袭淋巴系统,是一种治愈率较高的淋巴瘤,评估预后因素对于疾病的诊断和治疗有重要作用。近年来国际上研究的方向是化疗结合放疗、个体化治疗、积极尝试新药和新的治疗方式,以期提高患者的生存率。目前各研究组织提出的分级标准对风险调整治疗策略有重要的指导意义。也有研究提出低毒有效的联合化疗方案、正电子发射计算机断层扫描引导的放射治疗和靶向治疗药物。文章结合2017年美国国家综合癌症网络(NCCN)HL指南,就HL的临床病理特征、鉴别诊断诊疗方法的进展作一综述。

Hodgkin lymphoma (HL) is a kind of malignant tumors originating from lymphoid hemopoietic tissues and often involves lymphatic system. HL is a kind of highly curable lymphomas, and the assessment of prognostic factors is important for the diagnosis and treatment of this disease. In recent years, the international research focuses on the reasonable and individualized comprehensive treatment mode of radiotherapy and chemotherapy, the exploration of new drugs and new chemotherapy protocols, in order to further improve the survival rate of patients. Staging criteria from several research organizations have played the guiding role in the therapeutic strategy of risk adjustment. Some researches have proposed low toxic and effective combined chemotherapy regimens, radiotherapy and new targeted drugs guided by positron-emission tomography. Combined with the National Comprehensive Cancer Network (NCCN) in 2017 guidelines, this paper reviews the progresses of clinicopathological manifestations, differential diagnosis and treatment regimens of HL.